Results from the late-stage trial evaluating AstraZeneca's Calquence, or acalabrutinib, in adults who received prior treatment for high-risk chronic lymphocytic leukemia, showed that the drug was noninferior to Janssen and Pharmacyclics' Imbruvica, or
ibrutinib, in terms of progression-free survival. Complete trial data is still for submission and will be presented at a future medical meeting.